AstraZeneca Pharma India Limited announced a 37% revenue growth for the quarter ended September 30, 2025, driven by strong performance in Oncology and Biopharmaceuticals. Revenue for Q2 2025-26 reached ₹5,590.9 million, and H1 2025-26 revenue totaled ₹10,854.0 million. The company also highlighted seven new approvals in H1, reinforcing its leadership across key therapy areas.

Financial Performance Overview

AstraZeneca Pharma India Limited reported a significant 37% revenue increase for Q2 2025-26. The company’s revenue for the quarter ending September 30, 2025, reached ₹5,590.9 million. Overall, H1 2025-26 revenue totaled ₹10,854.0 million. This growth reflects disciplined execution and strong momentum in key therapeutic areas.

Key Financial Highlights

Here is a summary of the company’s financial performance (in INR Mn):

Total revenue from Operations, Q2 2025: 5,590.9

Total revenue from Operations, H1 2025: 10,854.0

Total revenue from Operations, Q2 2024: 4,080.0

Total revenue from Operations, H1 2024: 7,955.2

Profit before exceptional item and tax, Q2 2025: 781.1

Profit before exceptional item and tax, H1 2025: 1531.7

Profit before exceptional item and tax, Q2 2024: 510.3

Profit before exceptional item and tax, H1 2024: 934.3

Profit after exceptional item and tax, Q2 2025: 542.2

Profit after exceptional item and tax, H1 2025: 1100.5

Profit after exceptional item and tax, Q2 2024: 384.3

Profit after exceptional item and tax, H1 2024: 266.4

Performance by Therapy Area

The company witnessed robust growth across its therapy areas:

Oncology, Q2 2025: 3,977.5

Oncology, H1 2025: 7,673.6

Biopharmaceuticals (CVRM, R&I and V&I), Q2 2025: 1,267.5

Biopharmaceuticals (CVRM, R&I and V&I), H1 2025: 2,457.5

Rare Disease, Q2 2025: 38.1

Rare Disease, H1 2025: 42.3

New Drug Approvals and Milestones

AstraZeneca highlighted several key regulatory approvals and milestones including:

• Durvalumab: Received approval for additional indications in endometrial cancer treatment.
• Launched Eculizumab for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
• Osimertinib: Received approval for use in combination with chemotherapy for first-line treatment of NSCLC.
• Trastuzumab deruxtecan: Received approval for an additional indication in HER2-low and HER2-ultralow metastatic breast cancer patients.
• Osimertinib: Approval for monotherapy treatment of NSCLC.
• Benralizumab: Approval as an add-on treatment for EGPA.

Source: BSE

Aegis Logistics announces the availability of the audio recording of its earnings call discussing the unaudited financial results for the quarter and six months ended September 30, 2025. The call was held on November 07, 2025, at 2.30 p.m. (IST). The audio recording is accessible on the company’s website under the Investor Presentations section.

Earnings Call Recording Available

Aegis Logistics has released the audio recording of its earnings call pertaining to the unaudited financial results. This call covered the company’s performance for the quarter and six months period, which concluded on September 30, 2025.

Accessing the Recording

The earnings call, which took place on November 07, 2025, at 2.30 p.m. (IST), is now available for replay. Interested parties can access the audio recording through the Aegis Logistics website. The recording is located in the Investor Presentations section of the site.

Source: BSE

Ramkrishna Forgings announced that the National Company Law Tribunal (NCLT), Kolkata Bench, has approved the Second Motion Petition Order regarding the Scheme of Amalgamation. This scheme involves Mal Metalliks Private Limited and Multitech Auto Private Limited with Ramkrishna Casting Solutions Limited. The approval was granted on November 6, 2025, following the hearing on October 7, 2025.

Amalgamation Scheme Receives Approval

Ramkrishna Forgings has received a favorable order from the Hon’ble National Company Law Tribunal (NCLT), Kolkata Bench, concerning the proposed Scheme of Amalgamation. The approval pertains to the merger of Mal Metalliks Private Limited and Multitech Auto Private Limited into Ramkrishna Casting Solutions Limited.

Details of the Amalgamation

The Scheme of Amalgamation involves Mal Metalliks Private Limited, a step-down wholly-owned subsidiary, and Multitech Auto Private Limited, a wholly-owned subsidiary, merging with Ramkrishna Casting Solutions Limited, which is also a wholly-owned subsidiary of Ramkrishna Forgings. This decision follows earlier intimations on February 22, 2024, and September 05, 2025.

Tribunal’s Order

The Hon’ble National Company Law Tribunal, Kolkata Bench, heard the Second Motion Petition on October 07, 2025. The order, which was uploaded on the website of Hon’ble Tribunal on November 06, 2025, has officially allowed the Second Motion Petition filed. A copy of the order has been made available on the company website.

Source: BSE

Samvardhana Motherson International Limited has established the Motherson ESOP Trust to manage its employee stock option scheme. The trust, formed with an initial corpus of ₹10,000, will oversee the administration and implementation of the Samvardhana Motherson International Limited Employees Stock Option Scheme 2025. The trust aims to benefit employees by managing and transferring shares under the scheme, contributing to employee welfare and retention.

Motherson ESOP Trust Establishment

Samvardhana Motherson International Limited (Motherson) announced the establishment of the Motherson ESOP Trust, an irrevocable trust, to administer and implement its employee stock option scheme. The decision was formalized on November 7, 2025.

Trust Purpose and Management

The primary purpose of the Motherson ESOP Trust is to manage the Samvardhana Motherson International Limited Employees Stock Option Scheme 2025. The trust will acquire shares of the company through primary issuance or secondary acquisition and transfer shares to beneficiaries as per the scheme’s terms. The trust aims to foster employee benefits and manage equity-based compensation plans.

Trust Structure

The trust was established with an initial corpus of ₹10,000. The trustees will administer the trust property and ensure the welfare of the beneficiaries by dealing in movable and immovable assets according to the scheme. Arjun Puri and Gautam Mukherjee have been appointed as trustees. The trustees will hold the trust fund and apply it to carry out the provisions of the Scheme as defined in the Trust Deed.

Key Provisions of the Trust

The trust is irrevocable and will continue until specific events such as the winding-up of the Settlor or the termination of the trust. The trustees have powers to manage the trust, administer the scheme, and acquire shares. Additionally, the trust ensures compliance with applicable laws and guidelines, including insider trading regulations and code of conduct. The trust will refrain from entering into any derivatives contracts. The board also reserves the right to amend or alter the scheme, provided such changes do not harm the beneficiaries.

Benefits to Employees

The establishment of the Motherson ESOP Trust enables Samvardhana Motherson International Limited to attract, retain, and incentivize employees. The trust allows employees to benefit from the company’s growth through equity participation, fostering a sense of ownership and alignment with the company’s success.

Source: BSE

Kotak Mahindra Bank has responded to queries regarding significant volume fluctuations in its securities trading. The bank affirms adherence to disclosure norms and clarifies that market factors beyond its control influence trading volumes. The bank confirms its ongoing compliance with obligations related to the Securities and Exchange Board of India (SEBI) regulations.

Response to Stock Exchange Queries

Kotak Mahindra Bank addresses recent inquiries regarding a noticeable increase in the trading volume of the bank’s securities on stock exchanges. The communication, dated November 7, 2025, offers clarifications regarding these movements.

Bank’s Stance on Disclosure and Market Influence

The bank emphasizes that it consistently makes appropriate disclosures about events and information impacting its operations and performance. These disclosures are made in compliance with established regulatory standards. Additionally, the bank states that market factors, often beyond its direct control, can influence the trading volumes of its securities.

Commitment to Regulatory Compliance

Kotak Mahindra Bank reiterates its commitment to fulfilling its obligations. The bank will continue to adhere to all relevant regulations in its operations.

Source: BSE

Zydus Lifesciences has received tentative approval from the USFDA for Olaparib Tablets, 100 mg and 150 mg. These tablets are indicated for the treatment of specific types of ovarian, breast, pancreatic, and prostate cancers in patients with particular genetic mutations. Olaparib tablets had annual sales of USD 1,379.4 mn in the United States (IQVIA MAT Sept-2025).

USFDA Tentative Approval

Zydus Lifesciences Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Olaparib Tablets, available in 100 mg and 150 mg dosages. This approval, announced on November 7, 2025, marks a significant step in expanding the company’s portfolio of oncology treatments.

Olaparib Tablets Overview

Olaparib is prescribed for treating certain types of cancers, including ovarian, breast, pancreatic, and prostate cancers, specifically in patients with genetic mutations like the BRCA gene or other homologous recombination repair (HRR) genes. According to the announcement, Olaparib tablets recorded annual sales of USD 1,379.4 mn in the United States as of September 2025 (IQVIA MAT).

Strategic Growth

With this latest development, Zydus Lifesciences now holds 426 approvals and has filed 487 ANDAs since the commencement of its filing process in FY 2003-04. The production of Olaparib tablets will take place at Zydus Lifesciences Ltd, SEZ.

Source: BSE

Global Health (Medanta) reported a 15% year-over-year revenue growth and a 14% year-over-year EBITDA increase (excluding Noida) for Q2 FY2026. Key drivers include increased patient volumes and realizations. The company’s Noida hospital commenced operations in September 2025. Expansion projects continue with new beds added in Patna and ongoing developments in Mumbai and Guwahati.

Financial Highlights for Q2 FY2026

Global Health Limited (Medanta) announced robust financial results for the second quarter of fiscal year 2026:

• Total Income: INR 11,189 million, up 14.8% year-over-year.
• EBITDA (excluding Noida): INR 2,804 million, a 13.7% increase year-over-year, with a margin of 25.2%.
• Profit After Tax: INR 1,584 million, representing a 21.1% year-over-year growth.

Medanta Noida, which began operations in September 2025, contributed revenue of INR 39 million but incurred an EBITDA loss of INR 197 million for the quarter.

Operational Performance

Several key operational metrics contributed to the strong performance:

• Occupied bed days increased by 7.7% year-over-year.
• In-patient count rose by 12.7%, and out-patient count grew by 14.9% year-over-year.
• International Patients Revenue increased significantly by 48.5% year-over-year to INR 762 million.

During the quarter, 37 new beds were added at Patna, bringing the total new bed addition for H1 FY26 to 57.

Expansion and Projects

Medanta is actively pursuing expansion projects:

• Guwahati, Assam: Land acquisition and possession completed, with Bhoomi Poojan held on October 31, 2025.
• Mumbai: Project cost estimated at ~INR 15,300 million. Additional FSI approval received, increasing bed capacity to 750.
• Noida: Commenced Phase 1 with 226 beds operational as of Q2 FY26.

Capex Plan

The company has outlined a capex plan for the next five years, with a total outlay of approximately INR 41,200 million. This includes:

• Maintenance Capex: Estimated at INR ~4,500 million.
• Project Capex: Estimated at INR ~36,700 million, to be funded through debt and internal accruals.

Source: BSE

NALCO (National Aluminium Company Limited) is holding an earnings call today, November 7, 2025, to discuss the company’s business performance and outlook following the declaration of unaudited financial results for Q2 and the first half of FY 2025-26. The call is scheduled for 1800 hours. The company confirms that no unpublished price-sensitive information will be discussed during this call.

Earnings Conference Call

National Aluminium Company Limited (NALCO) will host an earnings conference call today, November 7, 2025, at 1800 hours to discuss the company’s performance. This call follows the release of the unaudited financial results for the second quarter (Q2: Jul-Sep) and the first half of fiscal year 2025-26.

Performance Highlights (H1 FY26)

NALCO reported strong physical performance for the first half of FY26. Key highlights include:

• Bauxite Transportation: 36.63 Lakh Tonne (9.64% increase)
• Alumina Hydrate: 11.53 Lakh Tonne (22.79% increase)
• Aluminium Cast Metal: 2.34 Lakh Tonne (3.00% increase)
• Net Power Generation: 3,429 MU (7.76% increase)

The company achieved the highest ever H1 Alumina Hydrate Production and the highest ever H1 Cast Metal Production.

In terms of sales, the company recorded:

• Alumina/Hydrate Sale: 7.00 Lakh Tonne (81.82% increase)
• Domestic Metal Sale: 2.26 Lakh Tonne (1.80% increase)

The company achieved the highest ever H1 Alumina/Hydrate Sale and the highest ever H1 Domestic Metal Sales.

Financial Performance (H1 FY26)

Key financial figures for the first half of FY26 (in Rs Crore) are:

• Net Sales: 8,048 (18.02% increase)
• Revenue from Operation: 8,099 (18.10% increase)
• Total Income: 8,374 (19.80% increase)
• EBIDTA (Excl. Exceptional Income): 3,693 (41.17% increase)
• PBT: 3,325 (47.52% increase)
• PAT: 2,497 (50.15% increase)

Strategic Business Highlights

NALCO is focused on the following strategic areas:

• Integrated Operations, Located Strategically
• Zero debt leverage
• Raw Material Securitization
• Expanded Refinery capacity
• Smelter capacity addition
• Export and Global Presence

Major Projects

NALCO is undertaking significant projects, including:

• Expansion of Bauxite Mines (Pottangi)
• Expansion of Alumina Refinery (5th Stream)
• Expansion of Aluminium Smelter
• Captive Power Plant

Focus on Sustainability

NALCO is committed to minimizing environmental harm and implementing effective risk management strategies. Key initiatives include afforestation, waste utilization, advanced pollution control technologies, and biodiversity protection.

Source: BSE

Torrent Pharmaceuticals has announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2025. The company reported a total revenue of ₹3302 cr for Q2 FY26, a 14% increase compared to Q2 FY25. For H1 FY26, the total revenue stood at ₹6480 cr, reflecting a 13% growth year-over-year. Key markets such as India, the United States, and Brazil have shown significant growth.

Financial Performance Q2 FY26

Torrent Pharmaceuticals’ unaudited consolidated revenue for Q2 FY26 reached ₹3302 cr, marking a 14% increase from ₹2889 cr in Q2 FY25.

Key highlights include:

• India: Revenue of ₹1820 cr, a 12% increase.
• United States: Revenue of ₹337 cr, a 26% increase.
• Germany: Revenue of ₹303 cr, a 5% increase.
• Brazil: Revenue of ₹318 cr, a 21% increase.
• Others: Revenue of ₹524 cr, a 20% increase.

Financial Performance H1 FY26

For the half-year ended September 30, 2025, Torrent Pharmaceuticals reported a total revenue of ₹6480 cr, a 13% increase compared to ₹5748 cr in H1 FY25.

Key highlights include:

• India: Revenue of ₹3631 cr, an 11% increase.
• United States: Revenue of ₹646 cr, a 23% increase.
• Germany: Revenue of ₹612 cr, a 7% increase.
• Brazil: Revenue of ₹536 cr, a 17% increase.
• Others: Revenue of ₹1055 cr, a 14% increase.

Source: BSE

Kalyan Jewellers India Limited announced a robust performance for the first half of FY26, with revenue reaching ₹15,125 Cr, a 31% increase year-over-year. Profit after tax (PAT) soared to ₹525 Cr, marking a 70% growth compared to the previous year. The company saw significant growth in both its India and Middle East operations. Strong Navratri sales contributed to the positive results.

Financial Performance Highlights

Kalyan Jewellers India Limited reported strong financial results for the half-year ended September 30, 2025. Key highlights include:

• Revenue: ₹15,125 Cr, a 31% increase compared to the same period last year (H1 FY25: ₹11,585 Cr).
• Profit After Tax (PAT): ₹525 Cr, a significant 70% increase year-over-year (H1 FY25: ₹308 Cr).

Q2 FY26 Performance

The company also demonstrated strong performance in the second quarter (Q2: Jul-Sep) of FY26:

• Consolidated revenue for Q2 FY26 stood at ₹7,856 Cr, reflecting a 30% growth compared to the corresponding period in the previous year.
• PAT for Q2 FY26 reached ₹261 Cr.

India Operations

Standalone revenue for the India business in Q2 FY26 was ₹6,843 Cr, a 31% increase year-over-year. PAT for Q2 FY26 was ₹262 Cr.

Middle East Operations

The Middle East segment also showed positive results, with revenue for Q2 FY26 reaching ₹866 Cr, an 8% increase compared to the previous year. PAT for Q2 FY26 was ₹15 Cr.

Candere Performance

Our lifestyle jewellery platform, Candere, recorded revenue of ₹93 Cr and a net loss of ₹9 Cr for Q2 FY26.

Management Commentary

Mr. Ramesh Kalyanaraman, Executive Director, commented on the results: “We are extremely happy with the excellent all-round performance during the recently concluded quarter with an exceptional nine days of Navratri sale to end the quarter on a very strong note. The pick up in the momentum that we witnessed during Navratri continued to the ongoing quarter as well. Same-store-sales-growth for the 30-day period ending Diwali was in excess of 30% on a like for like basis. We are upbeat about the ongoing wedding season across the country and are fully geared up with fresh collections and campaigns.”

Source: BSE